2023 Pharmaceutical M&A

2023 is expected to see an increase in M&A activity due to increased competition from biosimilars. Large Pharmaceutical companies need to secure assets to offset these losses.

Major Drug Sales Facing Revenue Declines

To meet investors' expectations for growth, large Pharmaceutical companies will continue to acquire products and platform technologies.

hasan-almasi-nKNm_75lH4g-unsplash Copy.j

SVI Can Help

Successfully partnering with a large pharmaceutical company requires experience. Advisors at Strategic Value Inflections have worked at major pharmaceutical companies and evaluated, valued, and assessed nearly 1,000 opportunities and successfully negotiated many multi-billion dollar agreements